A new version of the epilepsy medicine Lyrica (pregabalin) has failed to significantly reduce seizures during tests. The manufacturer Pfizer had hoped the new version of the medicine would mean people taking it just once a day. However, it didn’t show enough of an improvement in reducing seizure frequency.
Pfizer are still testing the once-a-day version of Lyrica for treating other conditions including fibromyalgia and some types of nerve pain.
This news does not affect how the current version of Lyrica should be used for treating epilepsy.
Source: uk.reuters.com and Pharma Times